Cigna Group (CI) Financials

Cigna Group’s latest quarter shows a mixed picture: solid profitability, but a much weaker operating cash flow profile and a more leveraged balance sheet than earlier periods. For Q1 2026, the company posted $1.86 billion in net income and $6.26 in diluted EPS, but operating cash flow fell sharply to $1.13 billion from $6.15 billion in Q4 2025 and $3.42 billion in Q3 2025.

Revenue and earnings remain substantial, but margins have compressed versus prior quarters. Q1 2026 revenue was $68.76 billion, up modestly from Q4 2025’s $72.30 billion but above Q1 2025’s $65.54 billion. However, pretax income of $2.27 billion was below the recent quarter-to-quarter peak, while Q1 2026 net margin was about 2.7%, lighter than several 2025 quarters.

• Strong quarterly profitability: Q1 2026 net income of $1.86 billion and diluted EPS of $6.26 indicate the business is still generating meaningful earnings power.
• Revenue base remains large and resilient: Q1 2026 revenue of $68.76 billion compares favorably with the prior-year first quarter and shows the company’s scale.
• Solid premium revenue trend: Premiums earned rose to $9.81 billion in Q1 2026 from $9.29 billion in Q4 2025 and $9.16 billion in Q2 2025.
• Retained earnings continue to build: Retained earnings increased to $49.1 billion at the end of Q1 2026 from $44.5 billion a year earlier, reflecting cumulative profitability.
• Cash balance improved quarter over quarter: Cash and equivalents rose to $7.04 billion in Q1 2026 from $6.03 billion in Q3 2025.
• Shares outstanding are relatively stable: Weighted average diluted shares were essentially unchanged at 264.5 million in Q1 2026, limiting dilution concerns for now.
• Balance sheet remains large, but leverage is significant: Total assets were $153.27 billion versus total liabilities of $110.82 billion, leaving a thinner equity cushion than many investors may prefer.
• Goodwill and intangible assets remain sizable: Combined goodwill and intangibles were about $72.85 billion in Q1 2026, which is worth monitoring for impairment risk if operating performance weakens.
• Operating cash flow weakened sharply: Q1 2026 operating cash flow of $1.13 billion was far below recent quarters, suggesting weaker cash conversion in the period.
• Debt load is elevated: Q1 2026 short-term debt of $43.63 billion and long-term debt of $29.37 billion indicate a meaningful leverage burden.

Trend summary: Over the last several years, Cigna has consistently produced strong revenues and profits, but the quarterly pattern has been uneven. Earnings generally held up well through 2024 and 2025, while cash flow was more volatile — including quarters with very strong operating cash generation and others with sharp declines. In the latest quarter, the biggest concern is not profitability itself, but the drop in operating cash flow and the company’s still-heavy debt position.

Bottom line: Cigna still looks like a highly profitable, cash-generative healthcare company, but investors should watch whether Q1 2026’s weak operating cash flow was temporary or the start of a softer trend. If cash generation rebounds, the current earnings base could support further shareholder returns. If not, the balance sheet and leverage could become more important issues.